Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable morbidity and mortality. A wide array of drugs are available to treat PAH in the U.S. market. Phosphodiesterase-5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are the most prescribed first-line treatments; the more-efficacious prostacyclin therapies are used in later lines. Branded therapies feature highly in the PAH treatment algorithm, and combination therapy is common. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated PAH patients receive pharmacotherapy in the United States.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PAH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAH patients?
- How have Uptravi, Orenitram, Opsumit, Adempas, and Tyvaso been integrated into the treatment algorithm, and what is their source of business?
- What impact has the launch of Tyvaso DPI had on existing inhaled prostaglandin therapies?
- What percentage of PAH patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of PAH patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States.
Key companies: United Therapeutics, Actelion, Pfizer, Bayer, Gilead.
Key drugs: Opsumit, Tyvaso, Tyvaso DPI, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, ambrisentan, bosentan, sildenafil, tadalafil, epoprostenol.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes. The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Table of contents
- Pulmonary Hypertension - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Pulmonary Arterial Hypertension US March 2023
- Treatment Algorithms CDA Pulmonary Arterial Hypertension 2023 Dashboard
Anuhya V., M.Pharm., is a research associate on the Cardiovascular, Metabolic, Renal, and Hematological Disorders team at Clarivate. She conducts extensive secondary market research for a variety of CMRH indications, including pulmonary hypertension (PH), nonalcoholic steatohepatitis (NASH), heart failure (including HFrEF & HFpEF). She holds a M.Pharm. degree in general pharmacy from BITS Pilani in India and a bachelor’s degree in pharmacy from G. Pulla Reddy College of Pharmacy, which is affiliated with Osmania University, in Hyderabad, India.